BPC-157 'Wolverine' Peptide Use Surges 33-Fold in US, Study Finds

Use of the unapproved peptide Body Protection Compound-157 (BPC-157), widely dubbed the “Wolverine peptide” for its touted tissue-healing capabilities, has surged 33-fold in the United States since 2020, according to a Reuters report and accompanying academic study published in mid-September 2026. The dramatic rise highlights a widening gulf between strict FDA compounding restrictions and surging consumer demand.

The findings document an exponential increase in self-reported use, online sales, and discussion of BPC-157 between 2020 and 2026. The surge has been propelled by high-profile endorsements from biohacking media, sports podcasters, and public figures—most notably U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has frequently voiced support for expanded access to experimental research peptides.

33-Fold Surge in Consumer Adoption

The research tracks BPC-157’s transition from a niche research compound studied in animal models to a mainstream consumer phenomenon. Between 2020 and mid-2026, self-administered usage and inquiry volume increased 33-fold across national demographic cohorts.

Much of this growth reflects public interest in rapid recovery from orthopedic injuries, joint pain, and tendon damage. BPC-157—a synthetic 15-amino-acid peptide derived from a human gastric juice protein—gained its “Wolverine” moniker in online fitness communities due to animal studies suggesting accelerated tendon-to-bone healing and anti-inflammatory activity.

However, clinical researchers emphasize that this popular adoption has far outpaced human safety data. The 33-fold figure is a documentation count, not a prevalence estimate: newly documented users per quarter went from 4 (Q1 2020) to 134 (Q1 2026). The full series, cohort and sourcing are set out in How many people use BPC-157? The 2026 numbers. While preclinical rodent studies demonstrate promising angiogenesis and tissue repair mechanisms, robust phase 2 or phase 3 randomized human clinical trials remain virtually non-existent in peer-reviewed medical literature.

FDA Category 2 Restrictions vs. Gray-Market Sourcing

The 33-fold surge has occurred in direct opposition to federal regulatory policy. In late 2023, the U.S. Food and Drug Administration (FDA) placed BPC-157 on its Category 2 bulks list under sections 503A and 503B of the Food, Drug, and Cosmetic Act. Category 2 includes bulk drug substances identified as presenting significant safety risks or lacking sufficient clinical evaluation, effectively prohibiting state-licensed compounding pharmacies from legally compounding the substance.

The regulatory enforcement gap created an active gray market. As licensed compounding pharmacies withdrew BPC-157 from their official catalogs following federal warnings, consumer demand shifted toward online “research chemical” vendors and direct-to-consumer websites selling unverified vials labeled as “for laboratory research only.”

Many online vendors also market pre-mixed combinations known as the “Wolverine Stack”—blending BPC-157 with TB-500 (Thymosin Beta-4)—further complicating product oversight and dose consistency for self-administering individuals.

Clinical Deficit and Safety Warnings

Medical professionals and independent health organizations have raised concerns regarding the purity, sterility, and long-term biological effects of self-injected BPC-157.

These safety risks were underlined in 2026 by multiple product warnings. Independent patient safety organization ECRI issued a clinical warning regarding wellness peptide supply chains, while state health authorities instituted emergency recalls of unapproved injectable peptide formulations following endotoxin contamination incidents.

Furthermore, because BPC-157 promotes angiogenesis (the growth of new blood vessels), clinical researchers warn that unmonitored use could theoretically accelerate underlying vascular or neoplastic conditions—a potential side effect that requires rigorous clinical trial monitoring.

PCAC Recommendations and the 2026 Regulatory Outlook

The study’s release comes during a pivotal moment for federal peptide regulation. Following the FDA’s April 15 reclassification of 12 research peptides to an interim review tier, the Pharmacy Compounding Advisory Committee (PCAC) convened on July 23–24, 2026, to evaluate six key compounds.

During the July proceedings, PCAC voted in favor of recommending BPC-157 for inclusion on the 503A Bulks List under specified quality and sourcing standards, along with five other peptides (TB-500, KPV, MOTS-c, Semax, and Epitalon).

While the advisory committee’s vote marked a major policy shift toward formal compounding recognition, the FDA’s final binding rule remains pending. Until federal rulemaking is formally codified in the Federal Register, BPC-157 remains in an interim regulatory state, leaving state pharmacy boards and health systems to manage the ongoing surge in public use.

---

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.